C-XYOVZoe Biosciences
PAI-1, APJ, cardiometabolic disease
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-XYOV
C-XYOVC-XYOVPAI-1, APJ, cardiometabolic disease
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Zoe Biosciences PAI-1, APJ, cardiometabolic disease
Zoe Biosciences is developing best-in-class therapies to treat cardiometabolic disease. The company says it has leveraged decades of combined research to build therapies targeting PAI-1 and APJ. Its listed lead indications are heart failure with preserved ejection fraction, obesity, and sarcopenia.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Zoe Biosciences — Early mechanism · Bottom quartile. Derived deterministically from 7 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (2 programs at preclinical).…
Source: Deterministic